SIRPant Immunotherapeutics Inc. is a clinical stage company focused on the development of novel autologous macrophage cell therapy for treatment of aggressive tumors with unmet medical needs. SIRPant employs first-in-class macrophage-based cellular immunotherapy to drive robust and lasting immune responses that leverage downstream polyclonal killer T cells and polyclonal antibodies to target the tumor neo-antigens. In contrast to other forms of cellular immunotherapy, SIRPant utilizes a multi-pronged approach that engages multiple effector pathways simultaneously to elicit immunological response to treat cancer in a completely novel way. The company’s lead candidate is an autologous SIRPα-low activated macrophage therapy for the treatment of non-Hodgkin’s Lymphoma (NHL), under which the company intends to dose the first patient in Q4 2023. In Q4 2023 SIRPant filed a second IND for solid tumors.